ClinicalTrials.gg
WithdrawnNCT03417076Updated Sep 30, 2019

Absolute Bioavailability Study With Bexagliflozin

A Phase 1 interventional study of Bexagliflozin in Type 2 Diabetes Mellitus, sponsored by Theracos. Withdrawn at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-30.

Sponsored by Theracos · Phase 1, Interventional, and Treatment

How we know

Why this study was withdrawn
Sponsor decision to not initiate study due to sufficient bioavailability information

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 15 studies testing bexagliflozin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. Bexagliflozin · Diabetes Mellitus, Type 2.

Enrollment
15th of 15
0 · median 64
Started
2018
with 1 other
Phase 1
7 of 15
none open now
Registered
12th of 15
by date
Lead sponsor
13 of 15
Theracos

Among the 15 studies testing bexagliflozin in Diabetes Mellitus, Type 2, this one is the 15th largest by enrollment, is one of 2 that started in 2018, is one of 7 in phase 1, and was the 12th registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 15 studies testing bexagliflozin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About bexagliflozin

Bexagliflozin: first FDA approval 2023 (BRENZAVVY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing bexagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to determine the absolute bioavailability of bexagliflozin following a single oral dose co-administered with an intravenous dose.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • body-mass index () between 18.0 kg/m2 and 32.0 kg/m2
  • no nicotine and tobacco consumption in the past 3 months
  • willing and able to be confined to the clinical research facility as required by the protocol

Exclusion criteria

Exclusion Criteria:

  • history of allergy to drugs or latex
  • history of alcohol or drug dependence in the past 12 months.
  • donation of a significant amount of blood in the past 2 months
  • willing to use an adequate form of during the study and for 90 days after discharge from clinic
  • exposure to drug in the past 30 days or 7 half-lives of the investigational drug, whichever is longer
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Bexagliflozin

    Each subject will receive a single oral dose of bexagliflozin tablets, 20 mg, followed by a single IV dosing of \< 30 ug 14C-bexagliflozin in 0.9% saline solution).

    Drug: Bexagliflozin

Interventions

  • Bexagliflozin tablets, 20 mg, and bexagliflozin by IV

    Also known as: EGT0001442, EGT0001474

06

What researchers measure

Primary outcomes

  1. absolute bioavailability (Fp.o.) of bexagliflozin tablets

    oral to IV ratio of dose-normalized AUC0-inf (area under the plasma concentration time curve extrapolated to infinity)

    Time frame: Up to 48 hours

Secondary outcomes

  1. adverse events

    adverse event as a measure of safety and tolerability of treatment

    Time frame: Up to 3 days

07

Study locations

1 site
  • Clinical Research Site
    Madison, Wisconsin 53704, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2018; primary completion for Sep 2018, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2018
First posted
Jan 31, 2018
StartEst.
Aug 1, 2018
Primary completionEst.
Sep 16, 2018
CompletionEst.
Sep 16, 2018
Last update
Sep 30, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03417076
Lead sponsor
Theracos
Responsible party
Sponsor
First posted
Jan 31, 2018
Start date
Aug 1, 2018 (estimated)
Primary completion
Sep 16, 2018 (estimated)
Completion
Sep 16, 2018 (estimated)
Last update
Sep 30, 2019

Study contacts

Mason Freeman, M.D.
study director · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bexagliflozin

Start the discussion